2024 PARTNERS
Biodesix®
Expertise Partner
Biodesix is a pioneering leader in the field of diagnostic solutions. Our company specializes in end-to-end diagnostic services, with strengths in developing custom diagnostics, clinical sample testing, ddPCR™, and clinical proteomics. We are your dedicated partner and versatile diagnostic service provider with multi-omic technologies, a track record of successful collaboration with industry leaders, and an unwavering dedication to diagnostic innovation.
Tempus
Expertise Partner
Tempus is making precision medicine a reality through the power and promise of data and artificial intelligence. Tempus offers companion diagnostic development across our portfolio of assays, leveraging a broad-panel, universal platform used by thousands of oncologists globally. These assays can each incorporate multiple companion diagnostic markers, providing value across biopharma portfolios.
Reaction Biology
Exhibition Partner
Reaction Biology is a global contract research organization (CRO) that supports preclinical drug discovery with broad capabilities including protein and peptide production, over 2,000 biochemical and cell-based assays, biophysical testing, safety and toxicology, in vivo pharmacology models, and immuno-oncology services. Reaction also provides Good Manufacturing Practice (GMP) and Good Laboratory Practice (GLP) analytical and functional bioassays for testing potency, efficacy, and safety of large biological molecules.
Genialis
Innovation Partner
Genialis is a data science company putting people first to develop more effective drugs, and to allow us to make more targeted treatment decisions for better outcomes. Genialis ResponderID™ is a biomarker discovery platform that employs a people-first framework to model underlying disease biology. The platform marries this novel approach to biomarker conceptualization with proprietary technology, validated signatures and human data. The result is biomarkers that work in real patient populations and scale across clinical settings.
.
Certis Oncology
Innovation Partner
Certis Oncology is the only translational partner that combines the predictive power of artificial intelligence with advanced preclinical cancer models to evaluate efficacy and understand the complex mechanisms of action inherent to drugs that target RAS pathways. Whether you want to evaluate your RAS-targeted compound’s effect on previously radiated tumors in vitro, test it against immunotherapy-resistant subtypes in vivo, or investigate tumor microenvironment activity in humanized orthotopic patient-derived xenograft (O-PDX) cancer models, we support your forward-thinking approach to better translational data.
